JP2022551422A - ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 - Google Patents

ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 Download PDF

Info

Publication number
JP2022551422A
JP2022551422A JP2022518960A JP2022518960A JP2022551422A JP 2022551422 A JP2022551422 A JP 2022551422A JP 2022518960 A JP2022518960 A JP 2022518960A JP 2022518960 A JP2022518960 A JP 2022518960A JP 2022551422 A JP2022551422 A JP 2022551422A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
membered
cycloalkyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022518960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551422A5 (enExample
Inventor
リン バネン，
ミンナ ブイ，
ファミン ジャン，
ジャック マウン，
アンドリュー ラウブ，
ジャスティン サルヴァント，
ベンジャミン シパングラー，
キン ツォ，
ヨン ワン，
ウェイ シュー，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2022551422A publication Critical patent/JP2022551422A/ja
Publication of JP2022551422A5 publication Critical patent/JP2022551422A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022518960A 2019-09-26 2020-09-25 ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 Ceased JP2022551422A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906647P 2019-09-26 2019-09-26
US62/906,647 2019-09-26
US202063053530P 2020-07-17 2020-07-17
US63/053,530 2020-07-17
PCT/US2020/052850 WO2021062245A1 (en) 2019-09-26 2020-09-25 Pyridone compounds and methods of use in the modulation of a protein kinase

Publications (2)

Publication Number Publication Date
JP2022551422A true JP2022551422A (ja) 2022-12-09
JP2022551422A5 JP2022551422A5 (enExample) 2023-08-24

Family

ID=72827019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518960A Ceased JP2022551422A (ja) 2019-09-26 2020-09-25 ピリドン化合物およびタンパク質キナーゼの調節における使用の方法

Country Status (8)

Country Link
US (1) US12371428B2 (enExample)
EP (1) EP4034532A1 (enExample)
JP (1) JP2022551422A (enExample)
CN (1) CN114787144A (enExample)
AU (1) AU2020351782A1 (enExample)
CA (1) CA3155924A1 (enExample)
TW (1) TW202126651A (enExample)
WO (1) WO2021062245A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
US20240158393A1 (en) 2021-02-19 2024-05-16 Exelixis, Inc. Pyridone compounds and methods of use
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
JP2025500917A (ja) 2021-12-16 2025-01-15 キネート バイオファーマ インク． Ｍｅｔキナーゼの阻害剤
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
AU2024257603A1 (en) * 2023-04-17 2025-11-13 Celyn Therapeutics, Inc. Treatment of cancer with a met kinase inhibitor
WO2024217587A1 (zh) * 2023-04-21 2024-10-24 南京正大天晴制药有限公司 具有axl抑制活性的取代吡嗪化合物
WO2024259060A1 (en) * 2023-06-16 2024-12-19 Kinnate Biopharma Inc. Inhibitors of met kinase
CN117343046A (zh) * 2023-09-25 2024-01-05 辽宁大学 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
WO2025096463A1 (en) * 2023-10-30 2025-05-08 Vibliome Therapeutics, Llc Plk4 modulators
CN118878515B (zh) * 2024-06-19 2025-10-28 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
JP2009537632A (ja) * 2006-05-19 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
JP2014533287A (ja) * 2011-11-14 2014-12-11 セファロン、インク． ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体
WO2015012298A1 (ja) * 2013-07-24 2015-01-29 小野薬品工業株式会社 キノリン誘導体
WO2019080723A1 (zh) * 2017-10-26 2019-05-02 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN110041316A (zh) * 2018-01-17 2019-07-23 南京药捷安康生物科技有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013180949A1 (en) 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
CN104072480B (zh) 2013-03-27 2016-12-28 沈阳药科大学 喹啉类化合物及其制备方法和应用
WO2016104617A1 (ja) 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
CN108530426A (zh) 2017-03-02 2018-09-14 沈阳药科大学 含喹喔啉酮的4-苯氧基取代喹啉类化合物及其应用
CN109896997A (zh) 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
PT3842425T (pt) 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
WO2020042618A1 (zh) 2018-08-27 2020-03-05 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
WO2021043217A1 (zh) * 2019-09-06 2021-03-11 中国科学院上海药物研究所 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
CA3171473A1 (en) 2020-02-24 2021-09-02 Exelixis, Inc. Compounds and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
JP2009537632A (ja) * 2006-05-19 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
JP2014533287A (ja) * 2011-11-14 2014-12-11 セファロン、インク． ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体
WO2015012298A1 (ja) * 2013-07-24 2015-01-29 小野薬品工業株式会社 キノリン誘導体
WO2019080723A1 (zh) * 2017-10-26 2019-05-02 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN110041316A (zh) * 2018-01-17 2019-07-23 南京药捷安康生物科技有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLARK, ROGER ET AL.: "A flexible high content imaging assay for profiling macrophage efferocytosis", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 473, JPN7024003307, 2019, pages 112636, ISSN: 0005386453 *
LI, SAI ET AL.: "Discovery of novel type II c-Met inhibitors based on BMS-777607", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 80, JPN7024003309, 2014, pages 254 - 266, ISSN: 0005386451 *
ZHANG, WEI ET AL.: "Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold", MOLECULES, vol. 19(2), JPN7024003308, 2014, pages 2655 - 2673, ISSN: 0005386452 *

Also Published As

Publication number Publication date
EP4034532A1 (en) 2022-08-03
US12371428B2 (en) 2025-07-29
CN114787144A (zh) 2022-07-22
AU2020351782A1 (en) 2022-04-21
WO2021062245A1 (en) 2021-04-01
TW202126651A (zh) 2021-07-16
US20220315579A1 (en) 2022-10-06
CA3155924A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
US12371428B2 (en) Pyridone compounds and methods of use
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP6026427B2 (ja) 置換６，６−縮合窒素複素環化合物及びその使用
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
JP6820254B2 (ja) 治療用化合物およびその使用
JP2019516757A (ja) Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
EP3883575B1 (en) Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2019516759A (ja) がんの処置のためのピラゾロピリジン誘導体
JP2019518767A (ja) Ｃｘｃｒ４阻害剤およびその使用
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
EP4294804B1 (en) Pyridone compounds and methods of use
JP2025517733A (ja) ヘテロアレーン、それを含む医薬組成物、及びその使用方法
JP2023514725A (ja) 化合物および使用方法
JP2024509192A (ja) Ｈｐｋ１アンタゴニスト及びその使用
JP2019515932A (ja) チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物
CN117440951A (zh) 吡啶酮化合物和使用方法
JP2022538138A (ja) Ｃｘｃｒ４阻害剤およびその使用
HK40079501A (en) Heterocyclic inhibitors of cbp/ep300 and their use in treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250205

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250620